Pregnancy outcomes study for people exposed to risankizumab
Treatments studied
Part of Bones, joints & muscles, Digestive system, Skin clinical trials.
This study looks at pregnancy outcomes in people who took risankizumab during pregnancy (or shortly before getting pregnant). It compares them with pregnancies exposed to similar biologic medicines, to better understand risks and what to expect.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You live in the United States
- You are currently pregnant and will enroll during pregnancy
- You have a condition that risankizumab is FDA-approved to treat (like plaque psoriasis, psoriatic arthritis, or Crohn’s disease)
- For the risankizumab group: you took risankizumab during pregnancy (or within about 20 weeks before conception)
- For the comparison group: you took another similar biologic medicine during pregnancy, but not risankizumab
- You have not already had the pregnancy outcome (delivery or loss) before joining the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at women who used a topical eczema cream called ruxolitinib (Opzelura) or steroid creams during pregnancy. The goal is to compare pregnancy outcomes and baby health up to one year after birth.
This study compares the health of mothers and their babies in two groups: women with eczema who used ruxolitinib cream during pregnancy and those who did not. It aims to see if the cream is safe for both mother and child.
This study tests how well a medicine called Risankizumab works for people with psoriatic arthritis. It is for adults who have had symptoms for at least 6 months and have not had enough help from at least one other arthritis medicine.
This study follows pregnant people who took tildrakizumab to understand pregnancy outcomes and safety. It also compares them with pregnant people with the same underlying disease who did not take tildrakizumab during this pregnancy.
This study looks at how risankizumab (Skyrizi) affects the quality of life for adults with moderate-to-severe plaque psoriasis. It is an observational study, meaning no new treatments are given—researchers simply follow patients who are already being treated with risankizumab as part of their regular care.
This study follows children with Crohn's disease who have already started taking risankizumab. It aims to see how well the treatment works in real-world use.
Hear when a new Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.